A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier. Pairing enzalutamide with leuprolide cut the risk of death by more than 40% compared to standard therapy.
  |
| | | | | | | | | | | | | | | Join our 2-day email miniseries to learn how to boost your protein intake with expert-approved tips and recipes. | | | | | | | | | | | |   | | | | | Until then, |  | Take care of yourself, and we'll
see you again soon! | | | | View in browser
Did a friend send you this email? Subscribe here.
To see all newsletters, click here.
Privacy | Unsubscribe
We may feature your messages to our inbox within our content. Please do not provide any personal identifiable information. Replies may be edited for length and clarity. For more, see our Privacy Policy.
Our website services, content, and products are for informational purposes only. Healthline does not provide medical advice, diagnosis, or treatment and should not be used as a substitute for medical advice from a healthcare professional. Healthline encourages you to make any treatment decisions with your healthcare professional.
Every product we recommend has gone through either Healthline's or Optum Now's vetting processes. If you buy through links on this page, we may receive a small commission or other tangible benefit. Healthline has sole editorial control over this newsletter. Potential uses for the products listed here are not health claims made by the manufacturers. Healthline and Optum Now are owned by RVO Health.
© 2025 RVO Health
1101 Red Ventures Drive
Fort Mill, SC 29707 | | | |
